2017 Asembia Recap

Specialty drugs must have a proven therapeutic value to be covered by plan sponsors.

The high cost of treatment causes some payers to question coverage for these conditions.

Meeting accreditation standards in the temperature-sensitive distribution process requires careful monitoring.

Value-based care and direct and indirect remuneration fees among the hottest topics at annual summit.

Rheumatoid arthritis carries risks for several comorbidities that can affect organ systems, such as the heart and lungs.

Summit provides comprehensive mix of content and education, including clinical, financial, supply chain, and industry trends. 

Hurdles remain in adding college coursework dedicated to specialty pharmacy.

The summit provides a place for specialty pharmacy stakeholders to discuss the industry.

Collaboration between Specialty Pharmacy Times® and Zitter Health Insights honors exemplary efforts in the health care industry.

Understanding that CSTDs are not a monolithic category of products is an important priority for pharmacists. 

Comprehensive data collection in specialty pharmacy more important than ever.

The summit provides a place for specialty pharmacy stakeholders to discuss the industry.

New biologic drugs coming to market could transform the standard of care.

New agents for vision conditions related to diabetes show promise, but come with challenges.

The first of 2 showcase events in the specialty space brings thousands of stakeholders from pharmacies, manufacturers, and service providers.

Consolidation and drug costs will play a key role in the future of specialty pharmacy.

Strategic, operational, and legal hurdles must be conquered before implementing this contract.

Clearly defining a patient population is necessary to create a singular care framework.

A number of hurdles in HIV, including preventative efforts, still need to be addressed.

Each specialty pharmacy stakeholder has a different definition of value.

Ideal management of specialty drug costs involves an in-depth look at medical and pharmacy claims.

Payers and providers may be less likely to encourage the use of biosimilars due to multiple concerns.

Expert panel at Asembia discusses hurdles in health care reform.